|Mr. John Rodney Varner||Co-Founder, CEO, Sec. & Chairman||530.42k||N/A||1957|
|Dr. Julien L. Pham M.P.H., M.D., MPH||Pres & COO||453.46k||N/A||1977|
|Mr. Ryan M. Confer||Chief Financial Officer||358.23k||N/A||1982|
|Dr. Jack A. Roth FACS, M.D.||Chairman of Scientific & Medical Advisory Board||N/A||N/A||N/A|
Genprex, Inc. operates as a clinical stage gene therapy company. It is involved in developing various approaches to treating cancer, based upon a proprietary technology platform, including Oncoprex immunogene therapy for non-small cell lung cancer. Oncoprex that has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells and re-establishes pathways for apoptosis, or programmed cell death in cancer cells; and modulates the immune response against cancer cells, as well as blocks mechanisms that create drug resistance. The company was founded in 2009 and is headquartered in Austin, Texas.
Genprex, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.